For the first time, a pathogen-selective antibiotic is being developed by Debiopharm International to selectively treat Staphylococcal infection. As of now, broad spectrum antibiotics are the only option to treat the Staph infection but can cause alteration of gut microbiome that increases the risk of metabolic and immunological disorders.
Gut microbiome encompasses millions of beneficial bacteria that aids digestion and protects the gut lining from infections. Broad-spectrum antibiotics non-selectively kill all bacteria including normal gut microflora that are essential for nutrition absorption and optimal immune function.
Studies have shown that irrational use of broad-spectrum antibiotics particularly in early ages could increase the risk of obesity, celiac disease and secondary infections in the later stages of life.
The experimental drug acts by inhibiting a microbial enzyme that is essential for growth and replication of Staphylococcus aureus. In the pre-clinical study, the experimental drug has been shown to be shrunk pathogen population without causing significant colony reduction of the gut microbiome. However, no similar effects were observed in other groups that received amoxicillin, linezolid, moxifloxacin and clindamycin treatments.
The aim of the newer therapy is to minimize collateral damage of normal gut microbiome and to destroy the specific pathogen in a targeted manner.